target upgrad unit state go sg websit
intrigu inflect point
upsid tp
nc chang
view allergan deal strengthen bullish thesi
approv could increas upsid share current
much believ agn botox strength carri
patent headwind even without estim
share discount greater-than-worst-cas
impact biosimilar
competit humira us creat valuat anomali
histor proport also expect better launch two
highest-profil pipelin asset drive await share re-rat
chang expect sharehold approv deal bid
premium gener rational controversi allergan pre-empt ftc
intend divest brazikumab pro forma model consolid consensu
agn forecast impli upsid stand-alone ep forecast
agn growth sustain higher-margin think
announc long-term pro forma guidanc stand-alone basi
deal close would catalyst share
valu stock target price tp still base unweight averag
three-year forward ev/ebita multipl dcf automat discount stock
short long-term fundament stand-alone tp increas
remov risk adjust sykrizi rinvoq follow recent
fda approv yet increas tp reflect allergan deal
yet fulli approv howev pro forma basi valuat could rise
stand-alone tp impli premium global peer price-to-earnings believ
appropri balanc abbv short-term long-term fundament
estim dp project stand-alone tsr
could wrong stand-alone pro forma dcf assum us sale
humira fall per annum thereaft due biosimilar competit
drug taken chronic drug erod line what
happen acut use protein-bas cancer drug europ stand-alone dcf
would drop sykrizi rinvoq abbv import pipelin drug
neither gener profit would downsid pro forma group
ebita botox face aggress biosimilar competit would
downsid risk pro forma ebita forecast
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
creat via spin-out abbott lab pharma busi humira
treat autoimmun diseas rheumatoid arthriti account abbv
group revenu follow unsuccess attempt acquir shire bought
blood cancer specialist pharmacycl bid diversifi away humira
addit inflamm cancer abbv key area therapeut focu
virolog women health neurosci result publish long rang
includ risk-adjust non-humira revenu forecast excess
announc intent acquir us special pharma compani allergan
manufactur botox cash stock
product relev invest debat bn
 migrain
via knoll acquisit
via pharmacycl acquisit
discov intern co-
develop roch book sale
hous
licens boehring ingelheim
licens neurocrin bioscienc
relev propos acquisit allergan
invest debat
reason
reason
 requir mitig imbruvica patent expiri
mix track record spent acquir us right imbruvica
 spent secur ex-u right stemcentrx
cancer acquir complet written
near-term product launch trigger rerat
massiv patent cliff humira imbruvica
allergan celgen consolid sourc sg cross asset research/equ
investor dont like allergan deal
recap abbv offer acquir us rate equat premium uss
close share price day transact announc manag believ
deal approv allergan sharehold immedi accret
earn confid newco exceed abbv wacc year
absolut pe allergan
allergan rel
view share price sold aggress sinc announc three
reason firstli market disappoint hadnt elect acquir
innov us biotech compani vertex rate although botox mani therapeut
fda approv includ prevent migrain treatment overact bladder see
addendum perceiv mani investor cosmet product secondli allergan
hasnt execut well recent year chart final suspect consensu
concern allergan acquisit signal expect impact us
biosimilar competit humira aggress previou aspir
stand-alone pro forma sale growth
stand-alone pro forma ep growth
note allergan estim bloomberg although acquisit isnt
note allergan estim bloomberg although acquisit isnt
expect close earli pro forma growth rate
expect close earli pro forma growth rate
assum consolid
assum consolid
like allergan deal
prior announc transact forecast abbv stand-alone
sale growth would volatil next decad impact biosimilar
competit humira us global imbruvica blockbust blood cancer
drug patent expiri chart
stand-alone sourc sale bn sg estim
forma sourc sale bn sg estim
cinicriviroc relamorelin allergan forecast bloomberg consensu
recap humira largest-sel drug world market leader
anti-tnf segment treat inflammatori diseas caus overact immun system
 autoimmun diseas see tabl
anti-tnf product profil sale bn
everi
certolizumab sc
analys humira patent cliff threat
seem us market over-estim threat humira goe off-
patent us extrapol experi went off-pat europ
provid specif guidanc shape us eros curv humira
post entri biosimilar although note prior start biosimilar
competit europ us sale humira roughli twice sale outsid us
howev better comparison drawn eros curv remicad key
competitor us humira experi outsid us payer
structur two geographi differ exampl european countri
oper winner take tender biosimilar wherea us moreov us
much larger privat insur market europ
remicad humira us biosimilar
acknowledg us biosimilar version humira
biosimilar version remicad today tabl howev expect us sale
humira declin rate line
remicad exist trend believ royalti underpin settlement
secur manufactur biosimilar humira us market temper abil
aggress compet price
use consensu forecast calcul pro forma estim expect
acquisit complet mitig impact biosimilar competit humira
us earli howev think abbv enlarg cash flow courtesi
botox durabl meaning increas enlarg group strateg flexibl
ahead imbruvica patent expiri chart
note allergan estim bloomberg consensu allergan
note allergan estim bloomberg consensu allergan
consolid
consolid
still bullish stock
valuat pipelin drive rerat
announc allergan acquisit caus abbv absolut pe test new low
chart left mean pro forma basi stock materi outlier vs
global pharma peer sg estim chart left view abbv current valuat
underestim abil base busi pipelin sustain enlarg compani
fundament face humira imbruvica patent headwind chart right
forecast pro forma includ celgen
forecast pro forma includ celgen
acknowledg long product cycl pharmaceut industri mean
absenc catalyst take long time deep valu stock rerat believ
two near term launch could chang investor percept abbv long-term sustain
thu drive rerat share
recap result present long-rang lrp
target stand-alone risk-adjust non-humira revenu forecast
strategi present manag also target nomin
probability-weight sale skyrizi rinvoq respect sinc
compani publish solid phase data product see appendix henc
jpmorgan healthcar confer manag indic expect
product collect contribut risk-adjust sale forecast
note reiter guidanc call showcas allergan
approv fda emea
in-licens boehring ingelheim
view abbv current valuat discount limit success rinvoq skyrizi
market place much emphasi number new entrant class
see addendum enough sheer size market chart view
segment far like shape dynam rise tide one size
fit nb minimum cumul market share rinvoq skyrizi
impli abbv guidanc far less humira peak market share see chart
forma valuat assum merger approv
recap stock coverag base target price unweight
averag three-year forward ev/ebita multipl dcf combin design best
reflect stock short-term long-term growth prospect basi calcul
acquisit allergan would increas overal valuat newco
see tabl valuat impli newco would trade discount
peer short term ep believ would appropri balanc short-term strength
long-term challeng stand-alone target price increas
pipelin upgrad put model driven
remov risk adjust potenti blockbust skyrizi rinvoq follow
fda approv psoriasi rheumatoid arthriti respect
premium/discount sector
pharma pure play still assum premium sector
averag reflect averag growth
still assum wacc perpetu growth rate
nb prior announc allergan acquisit common pushback receiv
investor bullish thesi dcf valuat close
current share price tabl upgrad stand-alone dcf
current share price pipelin upgrad describ
could wrong
import stress diseas humira treat chronic debilit
effect treat result signific cost healthcar system increas
absente work therefor believ us patient well control
abbvi brand product switch onto biosimilar save money
howev acknowledg biosimilar probabl prescrib new patient
channel check also suggest biosimilar threat humira regard
seriou market believ compani manufactur equip biosimilar
compani need produc product say sell less
equip compani intend launch biosimilar humira
compani sell biosimilar version cancer drug like roch rituxan
recap stand-alone pro forma dcf
respect assum biosimilar competit caus us sale humira declin
wrong sale erod annum
impact biosimilar competit alreadi rituxan
europ stand-alone pro forma dcf would drop
respect still current share price els equal chart henc
view current share price market realli discount overli
pessimist scenario impact biosimilar competit humira us
stand-alone pro forma base
stand-alone dcf sensit annual us humira eros per-share forma dcf sensit annual us humira eros per-share
sg cross asset research/equ note percentag horizont axi denot annual
growth
explain two import drug abbv underli late stage pipelin
immuno-inflamm asset skyrizi risankizumab rinvoq upadacitinib forecast
cumul sale two drug account soc gen pro forma group sale
compound-annual-growth-rate chart right follow fda approv note
call upgrad guidanc sale skyrizi
argument sake neither drug ever gener profit would
downsid pro forma ebita forecast
blood cancer drug imbruvica venclexta collect account
pro forma group sale compound-annual-growth-rate see chart right
cll abund leukaemia adult caus bone marrow produc
mani white blood cell diseas first occur usual symptom
time patient suffer swollen lymph node fever weight loss tired cll
affect peopl global common men women
imbruvica sourc sale book
venclexta sale book
cll import growth driver forecast imbruvica venclexta
chart serv differ segment market former probabl
appropri patient mani comorbid wherea latter better serv
robust aggress form diseas fit patient see chart
understand imbruvica btk inhibitor caus seriou side-effect atrial
fibril heart flutter channel check indic date approv indic
around patient discontinu imbruvica even though danger
side-effect
astrazeneca acquir stake acerta pharma gain access
calquenc drug also btk inhibitor alreadi direct competitor imbruvica
fda approv mantl cell lymphoma mcl rare type blood cancer
astrazeneca believ calquenc deliv much select btk inhibit
imbruvica lower propens caus off-target activ thu less side-effect
henc compani confid calquenc disrupt cll market howev
note believ numer differ rate atrial fibrillation/bleed
function matur data rel imbruvica
astrazeneca first phase cll trial relapsed/remit r/r patient call ascend read-
posit june calquenc prove effect rituxan
bendamustin chemotherapi rituxan zydelig gilead also safer howev
channel check indic set standard care either imbruvica monotherapi
secur via reson phase trial venclexta rituxan base phase murano
larger treatment nave set cll astrazeneca publish posit headlin result
first phase trial elev tn publish full result medic
congress later studi calquenc compar gazyva howev
channel check suggest gazyva /- chlorambucil isnt commonli use cll
standard care either imbruvica gazyva imbruvica chlorambucil venclexta gazyva
henc view potenti calquenc set properli assess
public phase trial
forecast market share calquenc cll cll
respect chart right believ demand new btk inhibitor
cleaner side effect profil imbruvica share estim conserv
everi extra point cumul share gain calquenc cll cll
combin would impli downsid pro forma ebita forecast
botox botulinum toxin type deriv anaerob bacterium clostridium botulinum
acknowledg protein easi characteris howev unlik similarli size
biolog drug tabl compani believ threat biosimilar competit
botox extrem unlik unsurprisingli manag explor risk detail
allergan due dilig process also believ sever compani
unsuccess attempt replic botox manufactur process variabl
ferment isol purif process
size select high-profil protein-bas drug
cosmet therapeut
sg cross asset research/equ note kda kilodalton measur molecular weight protein
base consensu forecast allergan must use complianc purpos
allergan deal ratifi sharehold botox account sg pro
investor dont seem concern risk biosimilar competit market
chart left theori market wrong botox face aggress rituxan-
like biosimilar competit revanc partnership hope launch
biosimilar calcul would downsid risk
pro forma ebita forecast believ highli unlik biosimilar
entrant market like success discount alreadi proven
unsuccess market see addendum detail addit note allergan
forecast global penetr facial inject market increas
migrain moder sever recurr headach thought affect peopl global
triptan popular drug treat condit decad gener
version avail year howev patient use drug
respond recurr attack triptan also
contraind patient cardiovascular diseas risk vasoconstrict
narrow blood vessel new england journal medicin estim
advers event prevent american suffer migrain use
calcitonin gene-rel peptid cgrp play import role migrain patho-physiolog
moreov demonstr sever previou clinic trial small-molecul cgrp
receptor antagonist gepant effect treatment migrain
base consensu forecast allergan ubrogep phase treatment
acut migrain atogep prevent migrain phase collect account
sg pro forma group sale compound-annual-growth-rate see chart right
investor expect market new migrain drug exceed chart right
howev consensu assum ubrogep atogep moder
success market like domin aimvog emgal two monoclon
antibodi effect prevent diseas chart right
patent list fda orang book either ubrogep atogep
provid inform regard henc drug face gener
competit earli calcul would low singl digit percentag downsid
risk pro forma ebita forecast
us mn
summari financi statement us mn except ep dp
product sold
equival
total liabil equiti
depreci amortis
chang work capit
flow oper activ
purchas secur net
flow invest activ
net chang debt
purchas treasuri stock
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
botulinum toxin activ ingredi botox produc bacteria botulinum
product wide use cosmet remov facial wrinkl medic
treat migrain overact bladder botulinum occur natur synthet
harvest produc botox commerci quantiti natur state microb
harmless larger popul produc neurotoxin
botulinum toxin occur eight differ strain botox deriv type
lethal neurotoxin known man caus botul rare disabl paralyt ill
studi suggest singl gram kill peopl howev commerci product
caus sever advers reaction approv use small concentr
botox temporarili paralyz facial muscl block releas acetylcholin
neurotransmitt nerv cell
botox launch oculinum gener sale year
although allergan acquir botox wasnt late decad start
invest expand product approv applic chart
botox sale progress approv us
botox approv clinic indic countri also wide use off-label
differ applic product achiev global sale
consensu forecast revenu
current five fda approv botulinum toxin product chart market
expect grow chart major driver
expect increas penetr facial aesthet segment
estim facial aesthet segment account market sale
howev allergan believ categori still under-penetrated
elig popul use facial inject see chart compani also believ facial
aesthet grow mid high singl digit rate penetr reach
awar risk increas competit biosimilar brand discount
agre consensu chart botox unlik disrupt
enjoy high barrier entri
botox patent protect understand revanc collabor
develop biosimilar version product current preclin test howev
allergan strongli believ biosimilar competit highli unlik long time
ever due absenc clear regulatori approv pathway also
botulinum toxin complex structur make difficult replic
specif manufactur process signific variabl ferment
isol purif assay method impact product react human tissu
thu clinic perform
medic aesthet cash pay market clinics/practition bundl purchas
receiv volume-bas discount allergan success bundl botox
juvederm dermal filler latiss treatment inadequ eye lash coolsculpt non-
allergan process increas global salesforc ad also doubl
invest direct-to-consum dtc advertis social media platform
build brand loyalti
dysport xeomin discount heavili launch respect
share gain temper allergan loyalti program educ offer
investor quit rightli view expect botox moat remain deep despit launch
evolu jeuveau revanc tabl
botulinum toxin base product approv pipelin
market korea us approv feb
market korea us partner sought
market korea us lauch due
botox current fda approv aesthet indic glabellar forehead crow feet
line howev allergan develop addit two indic masset promin
lower face platysma promin neck approv masset expect
platysma allergan also develop liquid pre-filled version botox expect
approv along topic deliveri microneedl technolog formul long-
act formul botox
allergan bought bonti privat held biotech develop fast-
act short durat altern botox botulinum toxin type bont/ product
characteris rapid onset action within hour durat effect
also liquid formul neurotoxin nivobotulinum toxin develop
glabellar line crow feet line allergan expect approv bont/
allergan plan develop neurotoxin franchise
expect approv
expect approv
expect approv
expect approv
signific proport botox sale deriv off-label use usag unapprov
indic legal us use drug unapprov indic physician think
best cours treatment avail howev us law pharma compani
directli market product use
nb us fda ad black-box warn strictest warn put label
prescript drug sever botulinum toxin product includ botox stress risk
potenti life-threaten complic toxin spread far beyond inject site
action driven off-label use botox children cerebr palsi result
allergan agre plead guilti paid settl crimin civil liabil
relat promot botox unapprov indic lawsuit brought
us depart justic alleg allergan misbrand botox promot use
headach pain spastic juvenil cerebr palsi none approv
fda time lawsuit also alleg allergan help doctor file fals
reimburs claim off-label usag
allergan mandat pay virginia juri man
develop perman brain damag inject botox treat cramp tremor
 allergan settl case court undisclos sum
rinvoq inhibitor janu kinas jak inflammatori mediat
play import role sever autoimmun diseas drug approv fda
rheumatoid arthriti inflamm larg joint august product also
phase trial crohn diseas ulcer coliti two type inflammatori diseas
bowel well atop dermat type skin inflamm differ psoriasi
psoriat arthriti inflamm finger toe giant cell arter inflamm
anti-tnf product profil sale bn
week
sc
shown tabl anti-tnf drug approv use wide treat ra
howev disadvantag product administ inject either
subcutan vein pain and/or time consum
present upadacitinib baricitinib investig compound develop respect data present head-
to-head studi data deriv select-next select-beyond studi ra-build ra-beacon studi addit phase data baricitinib
shown addit phase studi upadacitinib on-going
jak inhibitor conveni anti-tnf former deliv
bodi tablet form howev perform first-in-class jak inhibitor
xeljanz underwhelm sale fourth full year market
argu us reimburs hurdl sheer size rebat
tnf manufactur give insur compani rather xeljanz side effect profil
caus anaemia tired due lower red blood cell count
inhibit receptor anti-inflammatori effect caus block
increas risk cancer risk cite black box warn drug prescrib
hope differenti rinvoq xeljanz base safeti efficaci
claim rinvoq select theori mean
less like caus anaemia cancer risk associ rinvoq also
lower xeljanz select view
phase data suggest rinvoq highli competit profil chart
specif believ dose rinvoq provid strong differenti across
primari secondari endpoint includ strong result structur studi
superior humira head head trial also note olumi lli jak
inhibitor approv tnf-failur wherea rinvoq xelanz approv use
methotrex failur ahead tnf failur
note rinvoq receiv black stress thrombosi blood clot risk howev
label jak inhibitor warn tnf seriou infect
malign also note phase clinic trial wasnt increas
incid thrombosi patient treat rinvoq compar placebo prescrib
inform reflect
rinvoq sourc us revenu
psa/a psoriat arthriti ankylos spondyl uc ulcer coliti risk adjust
dermat psa/a psoriat arthriti ankylos spondyl gastro ulcer coliti
rinvoq chang sg forecast comparison consensu
forecast ahead consensu
increas forecast tabl reflect drug fda approv
 remov risk adjust estim ahead consensu
suspect market overestim potenti impact new entrant
underestim impact product cycl and/or underestim size market
in-licens global right skyrizi boehring ingelheim psoriasi
common chronic relapsing/remit auto-immun diseas characteris skin lesion red
plaqu usual itch psoriasi develop immun system mistak normal skin
cell pathogen send faulti signal caus overproduct new skin cell
sever diseas measur psoriasi area sever pasi
defin percentag bodi surfac cover plaqu less coverag
 two-third popul mild form diseas sever form psoriasi
affect less suffer
select new drug psoriasi
pasi week
vs placebo
titrat due gi side
effect
day
pasi week
vs placebo
week
month
pasi week
vs placebo
pasi week
market moder
phototherapi
system therapi
stelara
pasi week
vs placebo
pasi non
anti-tnf respond
phase pasi
sc everi
week two
load dose first
start dose
approv februari
us
black box warn
approv us
review europ
sc everi pasi vs
diseas clinic
coliti uc
last one
bimekizumab psoriasi
phase ii pasi
pasi
phase result pso
due
 week
pasi vs
humira week
psoriasi market domin topic agent phototherapi non-sever form
mainli corticosteroid mild-to-sever form treat system agent regard
latter largest class inject drug anti-tnf show good efficaci
patient time stelara launch becam
drug innov mechan action efficaci shown
tabl skyrizi belong class although sever potenti new
entrant market hope differenti product base efficaci
chart conveni unlik competitor dose everi three
skyrizi phase immvent studi moderate-to-sever psoriasi patient
skyrizi chang sg forecast comparison consensu
consensu forecast conserv
increas skyrizi forecast tabl reflect drug fda approv
skyrizi estim ahead consensu suspect market
overestim potenti impact new entrant underestim impact
product cycl and/or underestim size market tnf inadequ respond
estim us psoriasi patient treat biolog outsid
us estim level intern busi plan project nomin sale
skyrizi year estim sale
escap occur treatment longer effect
sourc us revenu
premium sector
chang wc
america corp
flow invest activ
flow financ activ
net chang cash result cf
intang
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
report complet sep cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
straight averag sotp base premium sector averag ev/ebita multipl dcf wacc termin growth
automat discount stock short long-term fundament
pro-forma dcf assum us sale humira declin due biosimilar competit drug taken chronic
eros ie line what happen acut use protein base cancer drug europ stand-alone dcf would
drop sykrizi rinvoq abbv import pipelin drug neither gener profit would
downsid pro-forma group ebita botox face aggress biosimilar competit would
downsid risk pro-forma ebita forecast
equiti rate dispers relationship
updat
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
